|Bid||0.3570 x 3000|
|Ask||0.3585 x 2200|
|Day's Range||0.3500 - 0.3749|
|52 Week Range||0.2310 - 2.2600|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 3,167,986 shares of the Company’s common stock.
AUSTIN, Texas & CAMBRIDGE, Mass.-- -- Company’s TUSC2 gene therapy found to increase effectiveness of anti-PD1 immunotherapy and anti-PD1 immunotherapy combined with platinum chemotherapy in humanized mouse model TUSC2 in combination with anti-PD1 and chemotherapy resulted in complete eradication of anti-PD1 resistant lung metastases Company’s Oncoprex™ immunogene therapy may improve on first-line ...
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month. Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer. Do not smoke, or if you smoke, then quit smoking – Tobacco, cigarettes and other smoking products all increase the risk of lung cancer.
AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one investor meetings. To learn more about the MicroCap Rodeo’s inaugural event October 15-16, 2019 in Austin, please visit microcaprodeo.com.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. A recently published paper by researchers in Australia, Spain and Austria supports the belief that non-viral delivery could be safer for patients than viral vectors and could speed up the production time while reducing the costs of production. “One of the biggest differentiators between Genprex and other gene therapy companies developing technologies to treat cancer and other serious diseases is our proprietary non-viral nanoparticle delivery system, which has already been used to safely treat more than 50 patients to date,” said Genprex’s Chairman and Chief Executive Officer, Rodney Varner.
Treatment for breast cancer varies, based on both the patient’s circumstances and type of cancer. The development of treatments to suppress or even eliminate cancer has led to a high survival rate in wealthy countries, with around 85% of patients in the United States and United Kingdom surviving for at least five years from diagnosis. Cancer is a difficult disease to defeat, and survival can depend upon the ability of scientists to counter a specific genetic defect in a specific set of cells.
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. Advances in biotechnology look to deliver promising new treatment options against breast cancer. Breast cancer is one of the most widely prevalent cancers in the world.
Imagined in the 1970s and first carried out in the 1980s, gene therapy is one of the newest frontiers in medicine. A number of companies have emerged with the aim of applying gene therapy to specific diseases. For example, Genprex Inc. (GNPX) specializes in tackling non-small cell lung cancer through its developmental drug Oncoprex(TM).
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector” and produced by NetworkNewsWire (“NNW”). With significant milestones being met, Genprex Inc. (GNPX) is pressing forward with its strategy objectives to reprogram the course of cancer. The company plans on continuing to conduct ongoing and new clinical trials as well as pursue strategic partnerships with organizations whose missions align with its own.
NEW YORK, Aug. 22, 2019 -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
Preliminary results show that Oncoprex has the potential to become an effective add-on therapy for the treatment of deadly non-small cell lung cancer. Genprex Inc. (GNPX) plans to expand the current erlotinib-Oncoprex trial to multiple research centers and conduct more new trials. If Phase II results are as positive as preliminary indications, it could spark a rally in the shares and possibly even lure a large biotechnology or pharma company to sign a high-value partnership with Genprex.
NEW YORK, May 30, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.